OctoPlus extends development agreement with ESBATech

Published: 24-Feb-2011
Research & Development Pharmaceutical

For controlled release product for ophthalmic indications


OctoPlus has entered into an agreement with ESBATech, a Biomedical Research Unit of Alcon, based in Zurich, Switzerland, for the development of a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications.

The agreement includes process development, scale-up and manufacturing for pre-clinical studies.

Financial details were not disclosed, but the Dutch firm said it would make a material contribution to its annual revenues in 2011.

This drug delivery technology evaluation project started in 2009. OctoPlus evaluated the feasibility of a controlled release formulation that combines an ESBATech proprietary eye care ingredient with the OctoPlus drug delivery technology PolyActive.

Jan Egberts, chief executive of OctoPlus, said: ‘I am delighted to see the success of our technology further validated in a product from such a prestigious company as ESBATech. We look forward to bringing this product to the next phase for ESBATech.

‘In addition to Locteron, this programme is now next in line in the commercialisation of the PolyActive controlled release technology.’

  • Companies:
  • OctoPlus
  • ESBATech
  • Alcon Group
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Future drug success is all in the delivery

Read more
Today, the mode of delivery can play a huge part in drug choice and success, thus new delivery technologies are proving to be a lucrative draw for drug formulators in all therapy categories. Susan Birks reports on market progress and predicted growth in the various categories

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  3. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Future drug success is all in the delivery

Today, the mode of delivery can play a huge part in drug choice and success, thus new delivery technologies are proving to be a lucrative draw for drug formulators in all therapy categories. Susan Birks reports on market progress and predicted growth in the various categories
Drug Delivery

Dr. Reddy’s Laboratories to acquire OctoPlus for €27.4m

Aims to build a research base in Leiden, The Netherlands
Manufacturing

OctoPlus signs agreement with pharma company to develop controlled release formulation

Of a therapeutic compound for local delivery into joints
Manufacturing

Octoplus extends drug delivery contract with Top-5 pharma company

Will combine product candidate with Octoplus PolyActive drug delivery technology
Finance

Novartis profit and sales up in Q2

Strong contribution from the Alcon eye care division
Finance

Novartis starts construction of US$500m plant in St Petersburg

Will produce new pharmaceuticals and generics for the Russian market
Drug Delivery

OctoPlus signs controlled release technology deal with US firm

Will use PolyActive technology to develop compound
Subscribe now